#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Myocarditis and inflammatory cardiomyopathy


Authors: J. Krejčí
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ;  Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně
Published in: Kardiol Rev Int Med 2015, 17(4): 288-294
Category: Cardiology Review

Overview

Myocarditis means an inflammation of the heart muscle, in the Czech Republic mostly of viral etiology. Infection may trigger immune and autoimmune mechanisms which contribute to the impairment of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Its typical manifestation is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging; the gold standard of diagnostics is invasive examination – endomyocardial biopsy. A significant number of cases with impaired left ventricular systolic function recover spontaneously and therefore it is appropriate to postpone critical therapeutic decisions until approximately 3–6 months after diagnosis. Therapy is based on the standard heart failure treatment. Immunosuppressive or antimicrobial treatment may be considered in some cases according to endomyocardial biopsy results. The most severe cases may require device therapy.

Keywords:
myocarditis – inflammatory cardiomyopathy – clinical course – diagnostics – treatment


Sources

1. Richardson P, McKen­na W, Bristow M et al. Report of the 1995 World Health Organisation/ International Society and Federation of Cardiology Task force on the definition and clas­sification of cardiomyopathies. Circulation 1996; 93: 841–842.

2. Caforio AL, Pankuweit S, Arbustini E et al. Cur­rent state of knowledge on aetiology, dia­gnosis, management, and therapy ofmyocarditis: a position statement of the European Society of Cardiology Work­ing Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648. doi: 10.1093/ eurheartj/ eht210.

3. Malik LH, Singh GD, Amsterdam EA. The epidemiology, clinical manifestations, and management of chagas heart disease. Clin Cardiol 2015; 38: 565–569. doi: 10.1002/ clc.22421.

4. Palecek T, Kuchynka P, Hulinska D et al. Presence od Bor­relia burgdorferi in endomyocardial bio­psies in patients with new-onset unexplained dilated cardiomyopathy. Med Microbio­l Im­munol 2010; 199: 139–143. doi: 10.1007/ s00430-009-0141-6.

5. Kubanek M, Sramko M, Berenova D et al. Detection of Bor­relia burgdorferi sensu lato in endomyocardial bio­psy specimens in individuals with recent-onset dilated cardiomyopathy. Eur J Heart Fail 2012; 14: 588–596. doi: 10.1093/ eurjhf/ hfs027.

6. Cooper LT jr. Myocarditis. N Engl J Med 2009; 360: 1526–1538. doi: 10.1056/ NEJMra0800028.

7. Kindermann I, Barth C, Mahfoud F et al. Update on myocarditis. J Am Coll Cardiol 2012; 59: 779–792. doi: 10.1016/ j.jacc.2011.09.074.

8. Den­nert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008; 29: 2073–2082. doi: 10.1093/ eurheartj/ ehn296.

9. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616–2625. doi: 10.1093/ eurheartj/ ehr165.

10. D’Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499–504.

11. Mason JW, O’Con­nell JB, Herskowitz A et al. A clinical trial of im­munosuppres­sive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269–275.

12. Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with „idiopathic“ left ventricular dysfunction. Circulation 2005; 111: 887–893.

13. Krejci J, Poloczkova H, Hude P et al. Impact of inflam­matory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor Vasa 2013; 55: e333–e340.

14. Kühl U. Antiviral treatment of myocarditis and acute dilated cardiomyopathy. Heart Fail Clin 2005; 1: 467–474.

15. Kuethe F, Lindner J, Matschke K et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009; 49: 1660–1666. doi: 10.1086/ 648074.

16. Escher F, Modrow S, Sabi T et al. Parvovirus B19 profiles in patients with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008; 14: 589–597.

17. Caforio AL, Calabrese F, Angelini A et al. A prospective study of bio­psy-proven myocarditis: prog­nostic relevance of clinical and aetiopathogenetic features at dia­gnosis. Eur Heart J 2007; 28: 1326–1333.

18. Kühl U, Las­sner D, von Schlippenbach J et al. Interferon-beta improves survival in enterovirus-as­sociated cardiomyopathy. J Am Coll Cardiol 2012; 60: 1295–1296.

19. Kindermann I, Kindermann M, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639–648. doi: 10.1161/ CIRCULATIONAHA.108.769489.

20. McCarthy RE, Boehmer JP, Hruban RH et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690–695.

21. Krejci J, Hude P, Poloczkova H et al. Cor­relations of the changes in bio­ptic findings with echocardiographic, clinical and laboratory parameters in patients with inflam­matory cardiomyopathy. Heart Ves­sels 2014. In pres­s. Available from: http:/ / link.springer.com/ article/ 10.1007/ s00380-014-0618-0#.

22. Baccouche H, Mahrholdt H, Meinhardt G et al. Dia­gnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial bio­psy in troponin-positive patients without coronary artery disease. Eur Heart J 2009; 30: 2869–2879. doi: 10.1093/ eurheartj/ ehp328.

23. Kuchynka P, Palecek T, Nemecek E et al. New ther­apeutic aspects on inflam­matory cardiomyopathy. Curr Pharm Des 2015; 21: 459–465.

24. Friedrich MG, Sechtem U, Schulz-Menger J et. al.Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 2009; 53: 1475–1487. doi: 10.1016/ j.jacc.2009.02.007.

25. Schumm J, Greulich S, Wagner A et al. Cardiovascular magnetic resonance risk stratification in patiens with clinical­ly suspected myocarditis. J Cardiovasc Magn Reson 2014; 16: 14. doi: 10.1186/ 1532-429X-16-14.

26. Grün S, Schumm J, Greulich S et al. Long-term fol­low-up of bio­psy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59: 1604–1615. doi: 10.1016/ j.jacc.2012.01.007.

27. Lauer B, Niederau C, Kühl U et al. Cardiac troponin T in patients with clinical­ly suspected myokarditis. J Am Coll Cardiol 1997; 30: 1354–1359.

28. Mahfoud F, Gärtner B, Kindermann M et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32: 897–903. doi: 10.1093/ eurheartj/ ehq493.

29. Heidecker B, Kittleson M­m, Kasper EK et al. Transcriptomic bio­markers for the accurate dia­gnosis of myocarditis. Circulation 2011; 123: 1174–1184. doi: 10.1161/ CIRCULATIONAHA.110.002857.

30. Cooper LT jr, Onuma OK, Sagar S et al. Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy. Heart Fail Clin 2010; 6: 75–85. doi: 10.1016/ j.hfc.2009.08.012.

31. Corsten MF, Papageorgiou A, Verhesen W et al. miRNA profil­ing identifies miRNA-155 as an adverse mediator of cardiac injury and dysfunction dur­ing acute viral myocarditis. Circ Res 2012; 111: 415–425. doi: 10.1161/ CIRCRESAHA.112.267443.

32. Bao JL, Lin L. MiR-155 and miR-148a reduce cardiac injury by inhibit­ing NF-κB pathway dur­ing acute viral myocarditis. Eur Rev Med Pharmacol Sci 2014; 18: 2349–2356.

33. Kühl U, Rohde M, Las­sner D et al. miRNA as activity marker in Parvo B19 as­sociated heart disease. Herz 2012; 37: 637–643.

34. Kühl U, Las­sner D, Dorner A et al. A Distinct subgroup of cardiomyopathy patients characterized by transcriptional­ly active cardiotropic erythrovirus and altered cardiac gene expres­sion. Basic Res Cardiol 2013; 108: 372. doi: 10.1007/ s00395-013-0372-y.

35. Yilmaz A, Kindermann I, Kindermann M et al.Comparative evaluation of left and right ventricular endomyocardial bio­psy: dif­ferences in complication rate and dia­gnostic performance. Circulation 2010; 122: 900–909. doi: 10.1161/ CIRCULATIONAHA.109.924167.

36. Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial bio­psy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 2013; 128: 1531–1541. doi: 10.1161/ CIRCULATIONAHA.13.001414.

37. Aretz HT, Bil­lingham ME, Edwards WD et al. Myocarditis. A histopathologic definition and clas­sification. Am J Cardiovasc Pathol 1987; 1: 3–14.

38. Baughman KL. Dia­gnosis of myocarditis: Death of Dal­las criteria. Circulation 2006; 113: 593–595.

39. Maisch B, Bultman B, Factor S et al. World Heart Federation consensus conference's definition on inflam­matory cardiomyopathy (myocarditis): report from two expert com­mittees on histology and viral cardiomyopathy. Heartbeat 1999; 4: 3–4.

40. Frustaci A, Rus­so MA, Chimenti C. Randomized study on the ef­ficacy of im­munosuppres­sive ther­apy in patients with virus-negative inflam­matory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995–2002. doi: 10.1093/ eurheartj/ ehp249.

41. Wojnicz R, Nowalany-Kozielska E, Wojciechow­ska C et al. Randomized, placebo controled study for im­munosuppres­sive treatment of inflam­matory dilated cardiomyopathy: two year fol­low-up results. Circulation 2001; 104: 39–45.

42. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-as­sociated myocarditis. N Engl J Med 2010; 362: 1248–1249. doi: 10.1056/ NEJMc0911362.

43. Bahk TJ, Daniels MD, Leon JS et al. Comparison of angiotension convert­ing enzyme inhibition and angiotension II receptor blocade for prevention of experimental autoim­mune myocarditis. Int J Cardiol 2008; 125: 85–93.

44. Saegusa S, Fei Y, Takahashi T et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expres­sion. Cardiovasc Drug Ther 2007; 21: 155–160.

45. Yuan Z, Shioji K, Kihara Y et al. Cardioprotective ef­fect of carvedilol on acute autoim­mune myocarditis: antiinflam­matory ef­fects as­sociated with antioxydant property. Am J Physiol Heart Circ Physiol 2004; 286: 83–90.

46. Pauschinger M, Rutschow S, Chandrasekharan Ket al. Carvedilol improves left ventricular function in murine coxsackievirus induced acute myocarditis as­sociation with reduced myocardial interleukin-1beta and M­mP-8 expres­sion and a modulated im­mune response. Eur J Heart Fail 2005; 7: 444–452.

47. Xiao J, Shimada M, Liu W et al. Antiinflam­matory ef­fect of eplerenone on viral myocarditis. Eur J Heart Fail 2009; 11: 349–353. doi: 10.1093/ eurjhf/ hfp023.

48. Cooper LT jr, Ber­ry GJ, Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicentre giant cell myocarditis study group investigators. N Engl J Med 1997; 336: 1860–1866.

49. Cooper LT jr, Hare JM, Tazelaar HD et al. Usefulness of im­munosuppres­sion for giant cell myocarditis. Am J Cardiol 2008; 102: 1535–1539. doi: 10.1016/ j.amjcard.2008.07.041.

50. Kandolin R, Lehtonen J, Salmenkivi K et al. Dia­gnosis, treatment, and outcome of giant-cell myocarditis in the era of combined im­munosuppres­sion. Circ Heart Fail 2013; 6: 15–22. doi: 10.1161/ CIRCHEARTFAILURE.112.969261.

51. Kawano S, Kato J, Kawano N et al. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern Med 2011; 50: 975–981.

52. Yanagisawa T, Inomata T, Watanabe I et al. Clinical significance of corticosteroid therapy for eosinophilic myocarditis. Int Heart J 2011; 52: 110–113.

53. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733–746. doi: 10.1007/ s10741-012-9358-3.

54. Frustaci A, Chimenti C, Calabrese F et al. Im­munosuppres­sive therapy for active lymphocytic myocarditis. Virological and im­munologic profile of responders versus nonresponders. Circulation 2003; 107: 857–886.

55. Palecek T, Krejci J, Pecen L et al. Czech Inflam­matory Cardiomyopathy Im­munosuppres­sion Trial (CZECH-ICIT): Randomized, multicentric study compar­ing the ef­fect of two regimens of combined im­munosuppres­sive therapy in the treatment of inflam­matory cardiomyopathy: The aims and design of the trial. Cor Vasa 2013; 55: 475–478.

56. Gul­lestad L, Aass H, Fjeld JG et al. Im­munomodulat­ing therapy with intravenous im­munoglobulin in patients with chronic heart fail­ure. Circulation 2001; 103: 220–225.

57. Den­nert R, Velthuis S, Schal­la S et al. Intravenous im­munoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial bio­psy-proven high PVB19 viral load. Antivir Ther 2010; 15: 193–201.

58. McNamara DM, Holubkov R, Starl­ing RC et al. Control­led trial of intravenous im­mune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254–2259.

59. Staudt A, Hum­mel A, Ruppert A et al. Im­munoadsorption in dilated cardiomyopathy: 6-month results from randomized study. Am Heart J 2006; 152: 712.e16.

60. Felix SB, Staudt A, Dörf­fer WV et al. Hemodynamic ef­fects of im­munoadsorption and subsequent im­munoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590–1598.

61. Kühl U, Pauschinger M, Schwim­mbeck PL et al. Interoferon – treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793–2798.

62. Zim­mermann O, Rodewald C, Radermacher M et al. Interferon β-1b therapy in chronic viral dilated cardiomyopathy – is there a role for specific therapy? J Cardiac Fail 2010; 16: 348–356.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#